Lobbying disclosures · Lobbying report
LLY: second_quarter 2026 lobbying report
Issues related to biotechnology legislation Diagnostic tests Clinical trial issues Issues related to supply chain Issues related to the pharmaceutical industry Treat and Reduce Obesity Act Pharmaceutical tariffs Safe Drugs Act
Follow LLY- Became public
- Jul 20, 2026, 8:58 AM EDT
- Event / period date
- Not stated
- Collected
- Nov 10, 2026, 6:12 AM EST
Why this is connected
Legal-name match: ELI LILLY AND COMPANY is ELI LILLY & Co (https://www.sec.gov/Archives/edgar/data/59478/), differing only in punctuation, "the" or suffix spelling (Corp/Corporation).
Reported lobbying amounts
Income: $90,000.00
These are different reporting measures. They are not added together or treated as spending on one particular bill.
Source evidence
Read the source excerpt or record
{"url":"https://lda.gov/api/v1/filings/9d3cb32b-987a-4a38-ad49-0a176c778ae2/","filing_uuid":"9d3cb32b-987a-4a38-ad49-0a176c778ae2","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/9d3cb32b-987a-4a38-ad49-0a176c778ae2/print/","filing_document_content_type":"text/html","income":"90000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"William Moschella, Attorney at Law","dt_posted":"2026-07-20T08:58:07-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":"United States of America","registrant_address_1":"600 Massachusetts Ave, NW","registrant_address_2":"Suite 400","registrant_different_address":false,"registrant_city":"WASHINGTON","registrant_state":"DC","registrant_zip":"20001","registrant":{"id":7257,"url":"https://lda.gov/api/v1/registrants/7257/","house_registrant_id":31842,"name":"BROWNSTEIN HYATT FARBER SCHRECK, LLP","description":"Law firm","address_1":"600 Massachusetts Ave, NW","address_2":"Suite 400","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20001","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"QUINN MCKAY","contact_telephone":"+1 202-872-5292","dt_updated":"2026-07-30T12:03:37.302760-04:00"},"client":{"id":110341,"url":"https://lda.gov/api/v1/clients/110341/","client_id":1009420,"name":"ELI LILLY AND COMPANY","general_description":"Pharmaceuticals","client_government_entity":false,"client_self_select":null,"state":"IN","state_display":"Indiana","country":"US","country_display":"United States of America","ppb_state":"IN","ppb_state_display":"Indiana","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2019-10-01"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Issues related to biotechnology legislation Diagnostic tests Clinical trial issues Issues related to supply chain","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":143188,"prefix":null,"prefix_display":null,"first_name":"BRANDT","nickname":null,"middle_name":null,"last_name":"ANDERSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":103206,"prefix":null,"prefix_display":null,"first_name":"ADAM","nickname":null,"middle_name":null,"last_name":"STEINMETZ","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":61089,"prefix":null,"prefix_display":null,"first_name":"ZACHARY","nickname":null,"middle_name":null,"last_name":"PFISTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70425,"prefix":null,"prefix_display":null,"first_name":"EMILY","nickname":null,"middle_name":null,"last_name":"FELDER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151303,"prefix":null,"prefix_display":null,"first_name":"STEPHEN","nickname":null,"middle_name":null,"last_name":"HOLLAND","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"Issues related to the pharmaceutical industry Treat and Reduce Obesity Act Pharmaceutical tariffs Safe Drugs Act","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":70425,"prefix":null,"prefix_display":null,"first_name":"EMILY","nickname":null,"middle_name":null,"last_name":"FELDER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":103206,"prefix":null,"prefix_display":null,"first_name":"ADAM","nickname":null,"middle_name":null,"last_name":"STEINMETZ","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143000,"prefix":null,"prefix_display":null,"first_name":"DEEMA","nickname":null,"middle_name":null,"last_name":"TARAZI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142877,"prefix":null,"prefix_display":null,"first_name":"GREGORY","nickname":null,"middle_name":null,"last_name":"SUNSTRUM","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151303,"prefix":null,"prefix_display":null,"first_name":"STEPHEN","nickname":null,"middle_name":null,"last_name":"HOLLAND","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":73587,"prefix":null,"prefix_display":null,"first_name":"DOUGLAS","nickname":null,"middle_name":null,"last_name":"FRIEDNASH","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":61089,"prefix":null,"prefix_display":null,"first_name":"ZACHARY","nickname":null,"middle_name":null,"last_name":"PFISTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}Congressional trading in LLY
These disclosures provide context. Their presence does not establish a link between a trader and the event.
- Nov 10, 2026$1K–$15K
Rep. Gilbert Ray Cisneros, Jr. (D-CA-31)
Bought Eli Lilly and Company LLY
$1K–$15K · Traded Oct 20, 2026 · disclosed Nov 10, 2026
Traded 9 days before earnings - Oct 7, 2026$1K–$15K
Rep. Ro Khanna (D-CA-17)
Bought Eli Lilly and Company LLY
$1K–$15K · Traded Sep 4, 2026 · disclosed Oct 7, 2026 · Spouse
- Aug 7, 2026$1K–$15K
Rep. Michael A. Rulli (R-OH-6)
Sold Eli Lilly and Company LLY
$1K–$15K · Traded Jul 1, 2026 · disclosed Aug 7, 2026
Committee overlap: Energy and CommerceGot $1K from the company’s PAC - Aug 7, 2026$1K–$15K
Rep. Michael A. Rulli (R-OH-6)
Bought Eli Lilly and Company LLY
$1K–$15K · Traded Jan 2, 2026 · disclosed Aug 7, 2026 · filed 217 days later
Committee overlap: Energy and CommerceGot $1K from the company’s PAC - Aug 7, 2026$1K–$15K
Rep. Michael A. Rulli (R-OH-6)
Sold Eli Lilly and Company LLY
$1K–$15K · Traded Dec 2, 2025 · disclosed Aug 7, 2026 · filed 248 days later
Committee overlap: Energy and CommerceGot $1K from the company’s PAC - Jul 21, 2026$1K–$15K
Sen. Alan Armstrong (R-OK)
Sold (full) Eli Lilly and Company LLY
$1K–$15K · Traded Mar 27, 2026 · disclosed Jul 21, 2026 · filed 116 days later
Committee overlap: HELP - Jul 17, 2026$1K–$15K
Rep. Dan Newhouse (R-WA-4)
Sold (partial) Eli Lilly and Company LLY
$1K–$15K · Traded Jul 10, 2026 · disclosed Jul 17, 2026 · Spouse
- Jul 2, 2026$50K–$100K
Rep. Gilbert Ray Cisneros, Jr. (D-CA-31)
Bought Eli Lilly and Company LLY
$50K–$100K · Traded Jun 10, 2026 · disclosed Jul 2, 2026
Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.